A Versatile Analytical Approach To Cleaning Validation For Multiple Linker–Payload ADC Platforms

Antibody–drug conjugates (ADCs) represent one of the most technically advanced classes of biopharmaceuticals, combining monoclonal antibodies with highly potent small-molecule cytotoxins via chemically engineered linkers. Unlike traditional antibodies or small molecules, ADCs function as integrated systems, where antibody structure, linker chemistry, and payload properties collectively influence drug–antibody ratio (DAR), stability, pharmacokinetics, and safety. The extreme potency of ADC payloads, while critical for therapeutic efficacy, introduces significant risks during manufacturing. Even trace residual linker–payload compounds on equipment can pose toxicological hazards, compromise product quality, or lead to unintended pharmacological exposure.

Addressing these risks requires highly sensitive analytical methods, rigorous cleaning validation, and comprehensive regulatory strategies. ADC manufacturing shifts the focus from conventional protein residue removal to controlling chemically diverse and potent compounds, demanding specialized detection and risk-management approaches. Linker–payload chemistry also presents bottlenecks in scale-up, as diverse physicochemical properties complicate purification, validation, and removal, while increasing cross-contamination risks in multi-product facilities.

To meet these challenges, integrated bioconjugation platforms provide flexible, standardized frameworks supporting various antibody formats, linker chemistries, and conjugation strategies. These platforms enable safe handling of potent payloads, ensure compatibility with downstream processes, and facilitate scalable production, balancing adaptability, quality, and manufacturability across the ADC lifecycle.